Cargando…

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?

Lung cancer is the leading cause of cancer-related mortality and will affect ~6% of the population. It is divided into two broad categories, small cell lung cancer and non-small cell lung cancer (NSCLC), the latter representing 85% of all lung cancers. It mainly comprises adenocarcinoma (65%) and sq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedlaender, Alex, Banna, Giuseppe, Malapelle, Umberto, Pisapia, Pasquale, Addeo, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433884/ https://www.ncbi.nlm.nih.gov/pubmed/30941314 http://dx.doi.org/10.3389/fonc.2019.00166

Ejemplares similares

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

Editorial: Molecular Characterization of Thyroid Lesions in the Era of “Next-Generation” Techniques
por: Bellevicine, Claudio, et al.
Publicado: (2022)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel
por: Malapelle, Umberto, et al.
Publicado: (2020)

Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
por: Malapelle, Umberto, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review
por: Thouvenin, Laure, et al.
Publicado: (2021)

Next generation sequencing in cytology
por: Pisapia, Pasquale, et al.
Publicado: (2021)

Leishmaniasis Vaccine: Where are We Today?
por: Kedzierski, Lukasz
Publicado: (2010)

Pathology of thymoma—where are we today?
por: Soomro, Irshad Nabi
Publicado: (2020)

Ocular tuberculosis: Where are we today?
por: Testi, Ilaria, et al.
Publicado: (2020)

Refractive surgery: Where are we today?
por: Sachdev, Mahipal S
Publicado: (2020)

Robotic Radical Cystectomy: Where are We Today, Where will We be Tomorrow?
por: Richards, Kyle A., et al.
Publicado: (2010)

Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases
por: Malapelle, Umberto, et al.
Publicado: (2016)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Psychopharmacology Today: Where are We and Where Do We Go From Here?
por: Schwartz, Thomas L.
Publicado: (2010)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
por: Addeo, Alfredo, et al.
Publicado: (2019)

HIV-2 Infection: Where Are We Today?
por: Ingole, Nayana A., et al.
Publicado: (2013)

Laboratory Information System – Where are we Today?
por: Lukić, Vera
Publicado: (2017)

Preimplantation Genetic Testing: Where We Are Today
por: Greco, Ermanno, et al.
Publicado: (2020)

Cryopreservation of single-sperm: where are we today?
por: Liu, Shasha, et al.
Publicado: (2020)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy
por: Banna, Giuseppe Luigi, et al.
Publicado: (2019)

Emotions and motivation in mathematics education: Where we are today and where we need to go
por: Schukajlow, S., et al.
Publicado: (2023)

Retrograde intra-renal surgery: Where are we today?
por: Chibber, Percy Jal
Publicado: (2008)

Magnetic Resonance Coronary Angiography: Where Are We Today?
por: Chiribiri, Amedeo, et al.
Publicado: (2013)

Pneumococcal vaccination in older persons: where are we today?
por: Van Buynder, Paul, et al.
Publicado: (2018)

Scleral surgery for the treatment of presbyopia: where are we today?
por: Hipsley, AnnMarie, et al.
Publicado: (2018)

Precision diabetes: Where do we stand today?
por: Mohan, Viswanathan, et al.
Publicado: (2018)

Oesophageal Adenocarcinomas: Where Do We Stand Today?
por: Karstens, Karl-Frederick, et al.
Publicado: (2020)

Cataract surgery – Where are we today and what do we need?
por: Heda, Aarti, et al.
Publicado: (2022)

Drugging KRAS: current perspectives and state-of-art review
por: Parikh, Kaushal, et al.
Publicado: (2022)

How can dementia and disability be prevented in older adults: where are we today and where are we going?
por: Lisko, I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5f3rrsmve2mbonekn2jeh74n97